GlobalData on MSN1d
Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial
Microbiotica has dosed the first subject in the Phase Ib MELODY-1 clinical trial of MB097, a precision microbiome co-therapy ...
PharmiWeb1d
Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma
Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab) Cambridge, UK – 10 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral ...
Business Weekly1d
Microbiotica progresses melanoma trial
Wellcome Sanger Institute spin-out Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision ...
MedPage Today on MSN13d
Novel Monoclonal Antibody Shows Promise in Ulcerative Colitis
Tulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...
IFA Magazine13d
EIS, EISA and its impact – Beauhurst 30th anniversary report
The Enterprise Investment Scheme Association's new report, in partnership with Beauhurst, looks into the impact of the ...
Outsourcing-pharma7d
Microbiome startup Sequentia Biotech heralds “new era” in omics with €10 million round
The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the ...
PharmiWeb15d
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement ...
icr.ac.uk1d
Multi-million-pound UK-wide platform into cancer immunotherapy launches
A new multimillion-pound research programme, involving scientists from The Institute of Cancer Research, London, is aiming to ...